<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OVERVIEW: Clinical indications for the use of interferons (IFNs) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> continue to expand and will likely continue to do so </plain></SENT>
<SENT sid="1" pm="."><plain>IFNs have been approved for clinical use by the United States Food and Drug Administration for <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> in the setting of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>, and <z:hpo ids='HP_0002861'>melanoma</z:hpo> for patients at high risk for recurrence after surgery </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, as a result of their antiviral activity, IFNs result in control of <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:hpo ids='HP_0012115'>hepatitis</z:hpo> and recurring <z:mpath ids='MPATH_445'>papillomas</z:mpath> that may reduce <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development resulting from these processes and their underlying viruses </plain></SENT>
<SENT sid="3" pm="."><plain>For almost <z:hpo ids='HP_0000001'>all</z:hpo> of these indications, therapeutic activity has been established from well-conducted, international phase III clinical trials </plain></SENT>
<SENT sid="4" pm="."><plain>IFNs were the first successful biological therapy for human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>; they can synergize to produce <z:mp ids='MP_0010537'>tumor regression</z:mp> with surgery and chemotherapy and can potentiate other cytokines and monoclonal antibodies </plain></SENT>
<SENT sid="5" pm="."><plain>IFNs and cytokines can modulate gene expression, resulting in enhanced immune effector-cell number, cytotoxicity, antigen expression, and production of other cytokines </plain></SENT>
<SENT sid="6" pm="."><plain>IFNs have pleiotropic effects on cellular function, including influences on growth, differentiation, and immunologic function </plain></SENT>
<SENT sid="7" pm="."><plain>For greatest effects, IFNs are used in combination with other modalities of therapy </plain></SENT>
<SENT sid="8" pm="."><plain>This increases the effect of IFNs or allows IFNs to increase the effects of other therapies </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="1" ids="16040">Cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> improves the therapeutic effectiveness of IFNs in <z:mp ids='MP_0005481'>CML</z:mp>, and IFN-&amp;agr;2b improves the prognosis, survival, and quality of life after surgery for high-risk patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Gene modulation by IFN-&amp;agr; or IFN-&amp;bgr; of <z:chebi fb="0" ids="17748">thymidine</z:chebi> phosphorylase, an enzyme important in DNA synthesis, has been suggested to be the basis for enhancing <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) effectiveness in preclinical models and may augment effectiveness in <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>IFNs increase the expression of some <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated antigens that could be of benefit for combination use with monoclonal antibodies for imaging or therapy </plain></SENT>
</text></document>